Mobia Medical Inc (MOBI) — Titan Protect Analysis

MOBI

Mobia Medical Inc

Healthcare · ·

$12.62

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$455M

Total market value of the company

Trailing P/E

N/A

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

-145.1%

How much profit the company keeps from each dollar of revenue

ROE

-246.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Mobia Medical Inc

Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The pa

https://www.mobia.com

Country: United States Employees: 167 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$14.77

15% below the year high

52W Low

$10.19

24% above the year low

Avg Volume

296,205

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.6

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.02

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

81.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-144.7%

Profit from core operations before interest and tax

Free Cash Flow

$-29,254,724

Negative — the business is spending more than it generates

Revenue (TTM)

$32M

Total revenue over the last 12 months

Net Income

$-46,498,188

Loss-making — spending exceeds revenue after all costs

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
7 Feb2025	Tim Walberg	Republican	buy	15K–50K
2026-04-17	Bill Keating	Democrat	Purchase	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go